| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Outline of Final Research Achievements |
Although fecal immunochemical test (FIT) has been widely adopted in many population based colorectal cancer (CRC) screening programs, its stage- and anatomical site-specific sensitivity for advanced colorectal neoplasms remains unclear. A total of 333 subjects [mean age: 63.9years, 176 males (52.9%)]with advanced neoplasms were prospectively enrolled. Of them, 219 had cancerous lesions [Tis (carcinoma in situ):54, T1:48, and T2 to T4:117]. The sensitivity of FIT for advanced adenoma, Tis, T1, and T2-4 cancers were 45.6% (36.3-55.2%), 48.1% (34.5-62.0%), 77.1% (62.3-87.5%), and 91.5% (84.5-95.6%), respectively. FIT had significantly lower sensitivity for proximally located lesions than distal ones in advanced adenomas (34.8% vs. 60.4%, P=0.008), cancers (64.5% vs. 84.6%, P=0.001), and invasive cancers (76.0% vs. 92.2%, P=0.006). FIT had significantly lower sensitivity for proximal located and early cancerous lesions.
|
